This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Osteoporosis  • Women's Health, Other  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Vogel and colleagues¹ reported the results of the Study of Tamoxifen and Raloxifene (STAR) P-2 trial. I was disappointed that in the accompanying Editorial, Drs Gradishar and Cella² did not comment on the role of the effects of raloxifene on the breast when choosing an agent to treat a patient with osteoporosis or osteopenia who has breast cancer risk factors. The MORE³ and CORE⁴ trials, while not performed on a group at high risk for breast cancer, showed a significant reduction in new-onset breast cancer. This may not be widely known because raloxifene is not approved for any breast indication.

Gradishar and Cella state that "decision making for an individual patient who is considering a preventive agent to reduce the risk of breast cancer must also take into account other health issues that may very well outweigh the risk of developing breast cancer." I would further . . . [Full Text of this Article]

Steven R. Goldstein, MD
steven.goldstein@med.nyu.edu
Department of Obstetrics and Gynecology
New York University School of Medicine
New York